The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
7-((4-methylpiperazin-1-yl)methyl)-3-(thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazole ID: ALA213743
PubChem CID: 44414347
Max Phase: Preclinical
Molecular Formula: C20H22N4S
Molecular Weight: 350.49
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: CN1CCN(Cc2ccc3c(c2)-c2[nH]nc(-c4ccsc4)c2C3)CC1
Standard InChI: InChI=1S/C20H22N4S/c1-23-5-7-24(8-6-23)12-14-2-3-15-11-18-19(16-4-9-25-13-16)21-22-20(18)17(15)10-14/h2-4,9-10,13H,5-8,11-12H2,1H3,(H,21,22)
Standard InChI Key: OLLCPXMBOYVHAF-UHFFFAOYSA-N
Molfile:
RDKit 2D
25 29 0 0 0 0 0 0 0 0999 V2000
6.6630 2.5394 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.6617 1.7117 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.3747 1.2987 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.3728 2.9521 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.0910 2.5434 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.0915 1.7163 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.8783 1.4612 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.8773 2.7993 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.3583 2.1319 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.1418 2.3830 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.1450 3.2058 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
9.3636 3.4630 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
10.8074 1.8954 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.8017 1.0742 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.5853 0.8160 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
12.0730 1.4817 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.5906 2.1510 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.9482 2.9513 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.2341 2.5386 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.5185 2.9585 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.8067 2.5494 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.8027 1.7244 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.5169 1.3101 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.2351 1.7208 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.0868 1.3142 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11 12 1 0
12 8 1 0
2 3 1 0
10 13 1 0
13 14 2 0
3 6 2 0
6 7 1 0
7 9 1 0
8 5 1 0
14 15 1 0
15 16 1 0
16 17 2 0
17 13 1 0
8 9 2 0
1 18 1 0
1 2 2 0
18 19 1 0
19 20 1 0
5 4 2 0
4 1 1 0
5 6 1 0
9 10 1 0
19 24 1 0
20 21 1 0
21 22 1 0
22 23 1 0
23 24 1 0
10 11 2 0
22 25 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 350.49Molecular Weight (Monoisotopic): 350.1565AlogP: 3.46#Rotatable Bonds: 3Polar Surface Area: 35.16Molecular Species: NEUTRALHBA: 4HBD: 1#RO5 Violations: ┄HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: 8.80CX Basic pKa: 7.88CX LogP: 3.21CX LogD: 2.89Aromatic Rings: 3Heavy Atoms: 25QED Weighted: 0.61Np Likeness Score: -1.62
References 1. Dinges J, Akritopoulou-Zanze I, Arnold LD, Barlozzari T, Bousquet PF, Cunha GA, Ericsson AM, Iwasaki N, Michaelides MR, Ogawa N, Phelan KM, Rafferty P, Sowin TJ, Stewart KD, Tokuyama R, Xia Z, Zhang HQ.. (2006) Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors., 16 (16): [PMID:16750628 ] [10.1016/j.bmcl.2006.05.052 ] 2. Dinges J, Ashworth KL, Akritopoulou-Zanze I, Arnold LD, Baumeister SA, Bousquet PF, Cunha GA, Davidsen SK, Djuric SW, Gracias VJ, Michaelides MR, Rafferty P, Sowin TJ, Stewart KD, Xia Z, Zhang HQ.. (2006) 1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors., 16 (16): [PMID:16759855 ] [10.1016/j.bmcl.2006.05.066 ]